REVEAL: CETP Inhibitor Anacetrapib Meets Primary End Point REVEAL: CETP Inhibitor Anacetrapib Meets Primary End Point

Anacetrapib significantly reduced major coronary events compared with placebo in patients at risk for cardiac events already receiving a statin in the REVEAL phase 3 study, Merck announced today.Medscape Medical News

Source: Medscape Medical News Headlines - June 27, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news